| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bausch Health Companies Inc.$4.95
+0.06 (+1.23%)
B 76Pipeline Score Undervalued Pharma · Commercial
Market Cap
1.87 B
EPS
-3.19
P/E Ratio
-1.57 $
Value Trade
12.83 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.52 B
R&D Expenses
163.00 M
Operating CF
230.00 M
Total Assets
24.50 B
Total Liabilities
25.58 B
Equity
-2.06 B
D/E Ratio
12,345
0.55 %
Week
-5.36 %
1 Month
-8.07 %
3 Month
-8.83 %
6 Month
-82.79 %
5 Year
994.01 %
All Time
Cash Data
Cash Position
1.31 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
687.12 K
52 Week Range
4.54 - 8.69
% held by Insiders
11.46 %
% held by Institutions
67.81 %
Enterprise Value
22.40 B
Total Shares
374.02 M
Short %
2.22 %
Float Shares
229.43 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bausch Health Companies Inc.
284Total events
2Upcoming
92Tier-1 (high impact)
2016 – 2029Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T1IP Litigation Ruling
Subscribe to view catalyst details
Event history 2
TBD
●Management ChangeCorporate
Subscribe to view catalyst details
TBD
▲Other Regulator MilestoneThermageEx-US Regulatory
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2023-10-20 | Cabtreo (adapalene) | PDUFA Date | PDUFA | Approved | – | – | – |
2023-10-20 | Cabtreo (adapalene) | PDUFA Date | PDUFA | Approved | – | – | – |
2023-10-20 | Cabtreo (adapalene) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
B76
Pipeline Score $16.4B
Pipeline ValueUndervalued
Valuation Signal46
Drugs Scored15.0x
rNPV / MCap Top 96%
Micro Cap (rank 37 of 912)
Percentile RankBausch Health Companies Inc. holds a solid B-grade pipeline (76/100), with $40.9B risk-adjusted pipeline value, led by Rifaximin in Diarrhea (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rifaximin Small molecule | Clostridium Infections | Phase 3 | NCT00269399 | 56% | $5.4B | COMPLETED | 237 | - | - | Dec 1, 2008 | - | Oct 14, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BHC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BHC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BHCBausch Health to Announce Second Quarter 2026 Results on July 29, 2026
Bausch Health Companies Inc. will release its second quarter 2026 financial results on July 29, 2026, after market close. A live conference call and webcast will be held at 5:00 p.m. U.S. EDT to discuss the results and provide a business update. The materials will be available on the Investor Relations section of their website prior to the call.
Read more →BHCMichael Goettler Resigns from Bausch Health's Board of Directors
Michael Goettler has resigned from Bausch Health's Board of Directors effective June 30, 2026, to assume the role of President and CEO at Knoa Pharma LLC. His departure was amicable and not due to any disagreements regarding the company's operations. Bausch Health expressed appreciation for his contributions during his tenure.
Read more →BHCBausch Health’s Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
Bausch Health's Solta Medical has received the AAA Well-Known Trademark Certification for its Thermage® brand in China, a prestigious recognition awarded to only 217 brands. This certification highlights Thermage's strong brand reputation and consumer confidence in the non-invasive aesthetic treatment market. The CEO emphasized the importance of this accolade in reinforcing trust among consumers and practitioners.
Read more →BHCBausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
Bausch Health's Solta Medical has achieved the AAA Well-Known Trademark Certification for Thermage® in China, a significant recognition awarded to only 217 brands. This certification underscores Thermage's strong brand reputation and consumer confidence in the non-invasive aesthetic treatment market. The CEO highlighted this achievement as a testament to their commitment to quality and innovation.
Read more →BHCBausch Health Announces 2026 Annual Meeting of Shareholder Results
Bausch Health Companies Inc. announced the successful election of all 10 director nominees during its 2026 Annual Meeting of Shareholders. Notably, Dr. Eiry W. Roberts was elected as a new director, bringing extensive experience in pharmaceutical leadership. Shareholders also approved the compensation for named executive officers and the appointment of PricewaterhouseCoopers LLP as the auditor.
Read more →BHCBausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference
Bausch Health Companies Inc. will participate in the RBC Capital Markets 2026 Global Healthcare Conference on May 20, 2026. CEO Thomas J. Appio and CFO Jean-Jacques Charhon will engage in a fireside chat, which will be available via a live audio webcast. A replay will also be accessible post-event.
Read more →BHCBausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
Bausch Health Companies Inc. will participate in the Barclays 30th Annual Leveraged Finance Conference on May 19, 2026. Company management will engage in a fireside chat, which will be accessible via a live audio webcast. A replay will also be available post-event, emphasizing the company's commitment to investor relations.
Read more →BHCInvestor Contact Media Contact Garen Sarafian Katie Savastano ir bauschhealth.com corporate.communications bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS Fir
Bausch Health Companies Inc. announced its financial results for the first quarter of 2026, reporting consolidated revenues of $2.52 billion, a 12% increase from the prior year. However, the company experienced a significant GAAP net loss of $1,423 million, largely due to a substantial goodwill impairment charge. Despite these losses, Bausch Health marked its twelfth consecutive quarter of revenue growth and a 32% increase in adjusted earnings per share. The company reaffirmed its full-year guidance while focusing on strategic investments in its pipeline.
Read more →BHCBAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year period...
Bausch Health Companies Inc. reported its first quarter 2026 financial results, showing a 12% increase in consolidated revenues to $2.52 billion. Despite this growth, the company faced a substantial GAAP net loss of $1,423 million, primarily due to a goodwill impairment charge. Adjusted earnings per diluted share rose to $0.78, reflecting a 32% increase from the previous year. The company reaffirmed its full-year guidance for revenue and adjusted EBITDA, indicating a focus on sustainable performance.
Read more →BHCBausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering
Bausch Health's Ortho Dermatologics has launched Biafine®, a skincare emulsion, available through select online channels in the U.S. This iconic French product, known for its ability to support skin hydration and barrier function, has been trusted by dermatologists since its introduction in 1971. The launch aims to provide easier access for patients and dermatology practices.
Read more →BHC▲ +7.4%on this news
Bausch Health to Announce First Quarter 2026 Results on April 29, 2026
Bausch Health Companies Inc. will release its first quarter 2026 financial results on April 29, 2026. A live conference call will be held at 5:00 p.m. U.S. EDT to discuss the results and provide a business update. The investor relations materials will be available prior to the call.
Read more →BHCBausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program
Bausch Health has launched the 2026 ASPIRE HIGHER Scholarship Program to assist six students affected by dermatologic conditions. Each scholarship will provide up to $10,000 for higher education. Applications are open until June 10, 2026, and recipients will be notified in July 2026. The program aims to recognize the achievements of these students and the healthcare providers supporting them.
Read more →BHCBausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical...
Bausch Health Companies Inc. and Solta Medical have launched the Clear + Brilliant® Touch laser in Canada, approved by Health Canada. This device enhances access to advanced skin rejuvenation treatments, reflecting the growing demand for non-invasive options. The system, suitable for all skin types, builds on the successful U.S. launch and aims to support both providers and patients.
Read more →BHCBausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of...
Bausch Health's OraPharma celebrates the 25th anniversary of ARESTIN® (minocycline HCl) Microspheres, the only FDA-approved locally applied antibiotic for periodontal disease. This milestone highlights the product's significant role in dental care, supported by over two decades of clinical experience. The company continues to focus on innovation and expanding access to treatment options.
Read more →BHCInvestor Contact Media Contact Garen Sarafian Katie Savastano ir bauschhealth.com corporate.communications bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2
Bausch Health Companies Inc. reported its fourth quarter and full-year financial results for 2025, showing an increase in consolidated revenues of 9% and a total of $2.80 billion for the fourth quarter. The company achieved its eleventh consecutive quarter of growth in both revenue and adjusted EBITDA, surpassing its guidance for the year. However, it reported a GAAP net loss of $112 million in the fourth quarter due to a goodwill impairment charge. The acquisition of a distribution business in China is expected to enhance its market reach and address demand in aesthetic treatments.
Read more →BHCBAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS Fourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP)1 basis over the prior year period ...
Bausch Health Companies Inc. reported strong financial results for Q4 and full-year 2025, with consolidated revenues of $2.80 billion, marking a 9% increase year-over-year. The company achieved its eleventh consecutive quarter of revenue and adjusted EBITDA growth, driven by successful acquisitions and operational excellence. However, it also faced a GAAP net loss of $112 million for the quarter, attributed to a goodwill impairment charge.
Read more →BHCBausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Executive Vice President and CFO Jean-Jacques (JJ) Charhon, along with other...
Bausch Health Companies Inc. announced that its Executive Vice President and CFO, Jean-Jacques Charhon, will participate in the J.P. Morgan Global Leveraged Finance Conference in Miami Beach from March 2-4, 2026. This event will provide an opportunity for the management team to meet with investors and discuss the company's strategies and performance. Bausch Health continues to focus on delivering better healthcare outcomes across various therapeutic areas.
Read more →BHCBausch Health Announces 2026 Gastrointestinal Health Scholars Program Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the...
Bausch Health has launched the 2026 Salix Gastrointestinal Health Scholars Program, offering scholarships of up to $10,000 to 10 students living with gastrointestinal diseases. The program aims to support these students in their pursuit of higher education. Applications are open until May 6, 2026, with recipients notified in summer 2026.
Read more →BHCBausch Health Provides Update on RED-C Phase 3 Clinical Trials
Bausch Health announced the results of its Phase 3 RED-C clinical trials, which evaluated amorphous-rifaximin SSD for preventing hepatic encephalopathy in liver cirrhosis patients. Despite being safe and well-tolerated, the trials failed to meet their primary endpoint. The company is reviewing the data for potential new development opportunities.
Read more →BHC▼ -10%on this newsshared move
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3 RED-C clinical program evaluating...
Bausch Health Companies Inc. announced the results of the Phase 3 RED-C clinical trials evaluating amorphous-rifaximin SSD for preventing hepatic encephalopathy in liver cirrhosis patients. Despite being safe and well-tolerated, the trials failed to meet their primary endpoint. The company is reviewing the data for potential new development opportunities.
Read more →BHC▼ -10%on this newsshared move
Investor Contact Media Contact Garen Sarafian Katie Savastano ir bauschhealth.com corporate.communications bauschhealth.com (877) 281-6642 (toll free) (908) 569-3692 Bausch Health Provides Update on RED-C Phase 3 Clinica
Bausch Health Companies Inc. announced the results of its Phase 3 RED-C clinical program, evaluating amorphous-rifaximin SSD for preventing hepatic encephalopathy in adults with liver cirrhosis. Despite the trials being safe and well-tolerated, they did not meet their primary endpoints. The CEO expressed disappointment and emphasized the company's commitment to exploring new treatment options. The trials involved over 1,000 participants across 17 countries, targeting a serious complication of liver cirrhosis.
Read more →BHCBausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
Bausch Health Companies Inc. will release its fourth quarter and full year 2025 financial results on February 18, 2026. The announcement will be followed by a live conference call at 5:00 p.m. U.S. EST to discuss the results and provide a business update. Investors can access materials on the company's website prior to the call.
Read more →BHCBausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026 Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2025 financial results after market close on Wednesday,...
Bausch Health Companies Inc. will announce its fourth quarter and full year 2025 financial results on February 18, 2026. The announcement will be followed by a live conference call at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All relevant materials will be available on their Investor Relations website prior to the call.
Read more →BHCBausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Bausch Health Companies Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 14, 2026. CEO Thomas J. Appio, along with other executives, will attend the event in San Francisco. A live audio webcast will be available, and a replay will follow on their investor relations website.
Read more →BHCBausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Thomas J. Appio, Chief Executive Officer, will participate at the 44th Annual...
Bausch Health Companies Inc. announced that CEO Thomas J. Appio will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The event will also feature other executives, including the CFO and Chief Medical Officer. A live audio webcast will be available, with a replay accessible afterward.
Read more →BHCBausch + Lomb Completes Refinancing of Outstanding Term B Loans
Bausch + Lomb Corporation announced the refinancing of its outstanding Term B loans through a new credit agreement totaling approximately $2.8 billion. This refinancing includes a reduction in the applicable margins, which will decrease interest costs and extend the maturity of certain loans. The new loans maintain the maturity date of the previous loans set for January 15, 2031, thus providing the company with additional financial flexibility. The move is part of Bausch + Lomb's ongoing efforts to strengthen its financial position.
Read more →BHCInvestor Contact Garen Sarafian ir bauschhealth.com (877) 281-6642 (toll free) Media Contact Katie Savastano corporate.communications bauschhealth.com (908) 541-3785 Bausch Health Announces Final Results and Expiration o
Bausch Health Companies Inc. has announced the final results and expiration of its exchange offers for outstanding Senior Secured Notes. As of the expiration time on December 23, 2025, the company reported that $2.7 billion of the Existing Senior Secured Notes were tendered. The company is set to issue approximately $1.6 billion of New Notes, with settlement expected to occur on December 26, 2025. This proactive measure demonstrates Bausch Health's commitment to managing its debt structure effectively.
Read more →BHCBausch + Lomb Announces Refinancing of Outstanding Term B Loans
Bausch + Lomb Corporation has announced a significant refinancing plan involving $2.8 billion in new term B loans intended to replace existing loans due in 2031 and 2028. This move includes reductions in interest rates for the replacement loans, helping to improve the company’s financial standing. The transactions are expected to finalize in the first quarter of 2026, though there are risks that could affect completion. Key forward-looking statements highlight the importance of closely monitoring these developments.
Read more →BHCInvestor Contact: Garen Sarafian ir@bauschhealth.com (877) 281-6642 (toll free) Media Contact: Katie Savastano corporate.communications@bauschhealth.com (908) 541-3785 Bausch Health Announces Launch of Offers to Exchange
Bausch Health Companies Inc. has announced an exchange offer for existing senior secured notes as part of its financial strategy to manage debt maturities. The company plans to exchange up to $1.6 billion of its outstanding 4.875% and 11.00% notes for new 10.00% senior secured notes due 2032. This move is supported by a transaction support agreement from holders of approximately 46% of the existing notes, ensuring participation in the exchange. The offers are set to expire on December 23, 2025.
Read more →BHCInvestor Contact Media Contact Garen Sarafian Katie Savastano ir bauschhealth.com corporate.communications bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2025 RESULTS Thi
Bausch Health Companies Inc. reported its financial results for the third quarter of 2025, showcasing significant revenue growth with consolidated revenues reaching $2.68 billion, up 7% from the previous year. The company has now achieved ten consecutive quarters of revenue and adjusted EBITDA growth, bolstered by the acquisition of DURECT Corporation. The business highlights include a net income of $179 million, a notable improvement from a loss the previous year, and the announcement of raising full-year guidance for revenue and adjusted EBITDA.
Read more →BHC▲ +11.1%on this news
Investor Contact: Media Contact: Garen Sarafian Katie Savastano ir@bauschhealth.com corporate.communications@bauschhealth.com (877) 281-6642 (toll free) (908) 569-3692 Bausch Health Announces Increase in Shareholding by
Bausch Health Companies Inc. has announced an increase in shareholdings by Paulson Capital Inc. and affiliates, acquiring over 34 million common shares previously held by Carl C. Icahn. This shift indicates a significant investor transition as the Icahn Group's agreement with Bausch Health has terminated, leading to the resignation of two Board members. Bausch Health's Chairperson, John A. Paulson, has expressed confidence in the company's future and business prospects.
Read more →BHC▼ -6.3%on this news
Investor Contact Media Contact Garen Sarafian Katie Savastano ir bauschhealth.com corporate.communications bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2025 RESULTS Se
Bausch Health Companies Inc. announced its financial results for the second quarter of 2025, reporting consolidated revenues of $2.53 billion, a 5% increase from the previous year. The company achieved its ninth consecutive quarter of growth in both Revenue and Adjusted EBITDA. Key highlights included a significant net income rise and the upcoming repayment of $900 million of debt. Bausch Health also positioned itself for future growth by acquiring DURECT Corporation, focusing on advancements in hepatology treatment.
Read more →BHCInvestor Contact: Media Contact: Garen Sarafian Katie Savastano ir@bauschhealth.com corporate.communications@bauschhealth.com (877) 281-6642 (toll free) (908) 569-3692 Bausch Health Announces the Appointment of Two New M
Bausch Health Companies Inc. has appointed Michael Goettler and Sandra Leung to its Board of Directors, expanding the board from ten to twelve members. Goettler, former CEO of Viatris, will enhance the board's Talent and Compensation and Science and Technology Committees. Leung, with significant experience as EVP and General Counsel at Bristol Myers Squibb, will contribute to the Nominating and Corporate Governance Committee. This move aims to leverage their insights and leadership for Bausch Health's continued growth and commitment to stakeholders.
Read more →BHCInvestor Contact: Media Contact: Garen Sarafian Katie Savastano ir@bauschhealth.com corporate.communications@bauschhealth.com (877) 281-6642 (toll free) (908) 569-3692 Bausch Health Appoints New Chief Accounting Officer
Bausch Health Companies Inc. announced the appointment of Steven Lee as the new Senior Vice President, Controller, and Chief Accounting Officer, effective July 14, 2025. Steven brings over twenty years of experience in financial transformation and strategic capital management from his previous roles at BrandSafway and Mohawk Industries. The company expresses enthusiasm about Steven's addition to the finance leadership team, as they continue their transformation journey focused on innovation and profitable growth.
Read more →BHCBausch + Lomb Announces Closing of Upsized 675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility
Bausch + Lomb Corporation announced the successful closing of a $675 million senior secured notes offering, alongside a partial refinancing of its existing credit agreements. The company secured a $2.325 billion term loan facility with a maturity in 2031 and an $800 million revolving credit facility set to mature in 2030. The proceeds from these offerings aim to repay existing borrowings and enhance operational flexibility. This move highlights Bausch + Lomb's efforts to strengthen its financial position as a leading global eye health company.
Read more →BHC▲ +7.9%on this news
Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering
Bausch + Lomb Corporation has announced the pricing of an upsized offering of senior secured notes totaling 675 million, up from an initial 600 million. This financing is part of the company's strategy to refinance existing loans and credit facilities, which includes a new term B loan facility and a revolving credit facility. The notes offering is set to close on June 26, 2025, and will strengthen the company's financial position.
Read more →BHCBausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement
Bausch + Lomb Corporation has announced the launch of a $600 million senior secured notes offering, alongside plans to refinance its existing credit agreement. The company aims to secure a new $2.2 billion term loan facility and an $800 million revolving credit facility to repay current borrowings and support general corporate purposes. The successful completion of these financial maneuvers remains subject to market conditions and other uncertainties. This initiative reflects Bausch + Lomb's commitment to strengthening its financial position.
Read more →BHCInvestor Contact Media Contact Garen Sarafian Katie Savastano ir bauschhealth.com corporate.communications bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2025 RESULTS Fir
Bausch Health Companies Inc. reported its first quarter 2025 results, revealing consolidated revenues of $2.26 billion, reflecting a 5% increase year-over-year. The company experienced its eighth consecutive quarter of revenue growth, excluding Bausch + Lomb, with performance driven by strong results across several segments. However, it reported a GAAP net loss of $58 million, although this was an improvement from the previous year's loss of $64 million. The company remains focused on maximizing shareholder value and maintaining its full-year financial guidance.
Read more →BHCInvestor Contact: Garen Sarafian ir@bauschhealth.com (877) 281-6642 (toll free) Media Contact: Katie Savastano corporate.communications@bauschhealth.com (908) 569-3692 Bausch Health Announces Adoption of Shareholder Righ
Bausch Health Companies Inc. has announced the adoption of a shareholder rights plan designed to ensure fair treatment of shareholders in potential unsolicited takeover bids. This plan will help the board identify and negotiate alternatives to any acquisition attempts. While the plan will require approval from shareholders within six months, the company emphasizes that it is not responding to any current takeover offers.
Read more →BHCInvestor Contact Media Contact Garen Sarafian Katie Savastano ir bauschhealth.com corporate.communications bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2024 RESULTS Six
Bausch Health Companies Inc. reported its third quarter 2024 results, showcasing a sixth consecutive quarter of revenue and Adjusted EBITDA growth. Total revenues reached $2.51 billion, a 12% increase from the previous year, driven by performance across all segments. The company is raising its full-year guidance and has improved its consolidated net loss significantly compared to the last year. However, the company still reported a net loss and highlighted ongoing high administrative costs.
Read more →BHCInvestor Contact Media Contact Garen Sarafian Katie Savastano ir bauschhealth.com corporate.communications bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2024 RESULTS Se
Bausch Health Companies Inc. reported its second quarter 2024 results, showing consolidated revenues of $2.40 billion, a rise of 11% compared to the previous year. The company also announced a 10% increase in adjusted EBITDA, reflecting robust operational growth and effective commercial strategies. Despite these positives, GAAP net income decreased, primarily due to higher operating expenses and interest costs. Bausch Health raised its full-year revenue and EBITDA guidance, indicating confidence in ongoing performance improvements.
Read more →BHCInvestor Contact: Media Contact: Garen Sarafian Katie Savastano ir@bauschhealth.com corporate.communications@bauschhealth.com (877) 281-6642 (toll free) (908) 569-3692 Bausch Health Welcomes Two New Members to the Execut
Bausch Health Companies Inc. announced the addition of two new members to its Executive Leadership Team, JJ and Aimee, who bring extensive experience in financial and operational roles. JJ previously served as CFO at Signant Health, while Aimee was Head of US Prescription Medicine at Galderma. This strategic move aims to support Bausch Health's transformation into a globally integrated healthcare company. CEO Thomas J. Appio expressed confidence in their leadership ability to enhance the company's objectives.
Read more →BHC▼ -7.5%on this news
Investor Contact Media Contact Garen Sarafian Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2024 RESULTS First
Bausch Health Companies Inc. has reported solid financial results for the first quarter of 2024, with revenues increasing by 11% to $2.15 billion compared to the previous year. The company demonstrated growth across all business segments and reaffirmed its financial guidance for the full year. However, the net loss attributable to Bausch Health was reported at $64 million, slightly improving from last year. Notably, the appeal decision concerning Xifaxan marks a significant milestone in the company's strategy for separating Bausch + Lomb.
Read more →BHC▲ +7.3%on this news
Investor Contacts Media Contact Solebury Strategic Communications Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FOURTH-QUART
Bausch Health Companies Inc. reported its financial results for the fourth quarter and full year of 2023, showcasing a revenue growth of 10% in Q4 and 8% for the full year, totaling $2.41 billion and $8.76 billion, respectively. The company noted significant advancements in its product segments, with particular growth in Salix and Bausch + Lomb. However, they reported a GAAP net loss of $39 million for the quarter and a larger loss of $592 million over the year. The CEO expressed optimism about the company's trajectory as it enters 2024, focusing on pipeline improvements and operational growth.
Read more →BHCInvestor Contact Media Contacts Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (908) 541-2102 (908) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Board Refreshment
Bausch Health Companies Inc. announced the nomination of two independent candidates, Christian A. Garcia and Frank D. Lee, for its Board of Directors as part of its commitment to board diversity and refreshment. The company also noted that current board members Russel C. Robertson and Thomas W. Ross, Sr. will retire and not seek re-election at the 2024 Annual Meeting. Garcia is expected to chair the Audit and Risk Committee while Lee will join the Talent and Compensation Committee and serve on the Science and Technology Committee. Further details and the complete slate of nominees will be provided in the company's upcoming proxy statement.
Read more →BHCInvestor Contacts Media Contact Lisa Wilson Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES THIRD-QUARTER 2023 RESULTS Revenue
Bausch Health Companies Inc. has reported its financial results for Q3 2023, showing a 9% increase in revenue to $2.24 billion, with growth in all business segments. The company also announced the FDA approval of CABTREOTM, a new topical treatment for acne, and provided updated guidance for full-year revenue and adjusted EBITDA. However, the company faced a significant net loss of $378 million and a drop in operating income due to rising expenses and impairments. Despite these challenges, Bausch Health remains focused on its R&D pipeline and commercial strategies.
Read more →BHCInvestor Contact: Mark Maico ir@bauschhealth.com (908) 541-2102 (877) 281-6642 (toll free) Media Contact: Kevin Wiggins corporate.communications@bauschhealth.com (908) 541-3785 Bausch Health s Bausch + Lomb Announces Com
Bausch + Lomb has completed the acquisition of XIIDRA, an eye drop treatment for dry eye disease, from Novartis for up to $2.5 billion. The deal includes an upfront payment of $1.75 billion and potential milestone payments of $750 million based on sales performance. This acquisition allows Bausch + Lomb to enhance its offerings in the ophthalmic care market and supports its strategy to improve patient outcomes in eye health. However, the financial implications of the acquisition raise concerns regarding cash flow and management focus.
Read more →BHCInvestor Contacts: Media Contact: John O'Connor Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (908) 541-2973 (908) 927-1198 Mark Maico ir@bauschhealth.com (908) 541-2102 (877) 281-6642 (toll
Bausch Health Companies Inc. announced the resignation of CFO Tom Vadaketh, effective October 13, 2023. The company will implement a search for his permanent replacement, during which John S. Barresi will assume the role of interim CFO. Barresi is currently Senior Vice President, Controller, and Chief Accounting Officer with over 15 years of industry experience.
Read more →BHCInvestor Contacts: John O Connor ir@bauschhealth.com (908) 541-2973 Media Contact: Kevin Wiggins coporate.communications@bauschhealth.com (908) 541-3785 Mark Maico ir@bauschhealth.com (908) 541-2102 (877) 281-6642 (toll
Bausch + Lomb has announced the launch of a proposed financing initiative totaling $1.4 billion to support its acquisition of XIIDRA and other ophthalmology assets. This financing includes the issuance of new senior secured notes and an incremental term loan facility, with expected proceeds designated for the acquisition, associated fees, and debt repayment. However, the closing of these financial offerings relies on market conditions, and completion is contingent upon the acquisition proceeding before September 30, 2024, or else the notes require redemption. Bausch Health emphasizes its commitment to improving lives with its diversified pharmaceutical portfolio.
Read more →BHCIndependent Auditors Report To Management of Novartis Pharma AG Report on the Audit of the Abbreviated Financial Statements Opinion We have audited the abbreviated financial statements related to the worldwide rights to
An independent auditor's report was conducted on the abbreviated financial statements of Novartis Pharma AG, relating to the rights to Xiidra, AcuStream, SAF312, and OJL332. The audit concludes that these statements fairly present the financial position of the assets acquired and obligations assumed as of December 31, 2022, and December 31, 2021. Novartis is in the process of divesting these assets to Bausch & Lomb for a total transaction value of up to $2.5 billion. The abbreviated financial statements are tailored to comply with SEC regulations and may not fully reflect the company's overall financial condition.
Read more →BHCInvestor Contacts Media Contact John O'Connor Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (908) 541-2973 (908) 541-3785 Mark Maico ir bauschhealth.com (908) 541-2102 (877) 281-6642 (toll f
Bausch Health Companies Inc. reported its second-quarter 2023 financial results, showing a 10% increase in revenue to $2.17 billion compared to the same quarter in 2022. The company highlighted a favorable legal decision regarding Xifaxan, reinforcing its Salix growth strategy, and announced improved liquidity exceeding $1 billion due to various balance sheet initiatives. Additionally, Bausch Health reaffirmed its revenue outlook for the full year and outlined advancements in its R&D pipeline, with several product approvals expected soon.
Read more →BHC▲ +8.5%on this news
Investor Contact: Media Contact: Mark Maico Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 Julia Kosygina media@kkr.com (212) 750-8300 Bausch Health
Bausch Health Companies Inc. has announced a $600 million non-recourse financing facility with KKR, providing additional liquidity for its operations. The facility will be secured by certain accounts receivables and is expected to support general corporate purposes over a term of approximately five years. This move reflects Bausch Health's ongoing strategy to strengthen its financial position and ensure operational efficiency.
Read more →BHCInvestor Contact: Media Contact: Mark Maico Kevin Wiggins ir@bausckhealth.com coporate.communications@bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 Bausch Health s Bausch + Lomb to Acquire Novartis
Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies Inc., has entered into a definitive agreement to acquire XIIDRA from Novartis for up to $2.5 billion. This deal includes an upfront payment of $1.75 billion in cash and additional milestones tied to sales performance. The acquisition, expected to close by the end of 2023, is projected to be immediately accretive. However, it hinges on receiving regulatory approvals, which brings some uncertainty to the completion of the transaction.
Read more →BHC▼ -20.4%on this news
Investor Contact Media Contact Mark Maico Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (908) 541-2102 (908) 541-3785 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES FIRST-QUARTER 2023 RE
Bausch Health Companies Inc. announced its first-quarter 2023 financial results, reporting revenues of $1.94 billion, a slight increase from the previous year. Core products achieved growth, notably Xifaxan with a reported increase of 7%. However, the company also reported a significant net loss of $201 million for the quarter, indicating operational challenges. Additionally, total operating income and adjusted EBITDA saw considerable declines compared to the same period last year.
Read more →BHCInvestor Contact Media Contact Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (514) 856-3855 (908) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Changes to its Board of Director
Bausch Health Companies Inc. announced the retirement of two board members, Richard De Schutter and Dr. Argeris Karabelas, effective from the upcoming annual shareholder meeting. Following their departures, the board will be reduced to 10 directors. The company acknowledges the significant contributions made by the retiring members. Additionally, certain board committees have been refreshed as part of this transition.
Read more →BHC▲ +14%on this news
Investor Contact Media Contact Mark Maico Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (908) 541-2102 (908) 541-3785 BAUSCH HEALTH ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2022 RESULTS Fourth
Bausch Health announced its fourth-quarter and full-year 2022 financial results, revealing total reported revenues of $2.2 billion for the fourth quarter, flat compared to the same quarter in 2021. The company reported a full-year revenue decline of 4%, attributed to factors including unfavorable foreign exchange impacts and divestitures. Despite these challenges, Bausch Health's CEO expressed optimism regarding their strategic priorities and plans for sustainable growth moving forward. Additionally, the company significantly reduced its debt by $464 million in the fourth quarter.
Read more →BHCInvestor Contact: Media Contacts: Christina Cheng Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces the Unrestric
Investor Contact: Media Contacts: Christina Cheng Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Docume
Read more →BHCInvestor Contact Media Contact Christina Cheng Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (514) 856-3855 (908) 541-3785 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES THIRD-QUARTER 20
Investor Contact Media Contact Christina Cheng Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (514) 856-3855 (908) 541-3785 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES THIRD-QUARTER 2022 RESULTS Revenues of $2.046 billion, down 3% reported,
Read more →BHCDocument Investor Contact Media Contacts Christina Cheng Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Final
Investor Contact Media Contacts Christina Cheng Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitati
Read more →BHC▲ +6.7%on this news
Document Investor Contact Media Contacts Christina Cheng Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Early
Investor Contact Media Contacts Christina Cheng Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicita
Read more →BHCInvestor Contact: Media Contacts: Christina Cheng Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Exchange Offe
Investor Contact: Media Contacts: Christina Cheng Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Se
Read more →BHCInvestor Contact: Media Contacts: Christina Cheng Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Continuing Process Towa
Investor Contact: Media Contacts: Christina Cheng Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Continuing Process Toward Separating Bausch + Lomb LAVAL, Quebec, Aug. 22,
Read more →BHC▼ -11.3%on this news
Investor Contact Media Contact Christina Cheng Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (514) 856-3855 (908) 541-3785 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2
Investor Contact Media Contact Christina Cheng Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (514) 856-3855 (908) 541-3785 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS Revenues of $1.967 billion Company to appeal
Read more →BHC▼ -41.2%on this news
Document Investor Contact Media Contacts Christina Cheng Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Provides Update
Investor Contact Media Contacts Christina Cheng Kevin Wiggins ir bauschhealth.com corporate.communications bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Provides Update Following Oral Order in XIFAXAN Patent Litigation -- Company to
Read more →BHCInvestor Contact: Christina Cheng christina.cheng@bauschhealth.com (514) 856-3855 (877) 281-6642 (toll free) Media Contact: Lainie Keller lainie.keller@bauschhealth.com (908) 927-1198 Bausch Health Announces 2022 Annual
Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors LAVAL, Quebec, June 23, 2022 Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health or the Company ) today announced the results of its 2022 annual meeting of shareholder
Read more →BHCAgenda 2 3 4 1 Call to order Procedural matters Voting items and results Management presentation 5 Q&A Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable sec
2021 Annual Meeting of Shareholders June 21, 2022 Exhibit 99.1 Agenda 2 3 4 1 Call to order Procedural matters Voting items and results Management presentation 5 Q&A Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applic
Read more →BHC▲ +7.8%on this news
of our Form 8-K filed on
On August 3, 2021, the Company announced its intentions to conduct an initial public offering ("IPO") of its aesthetic medical device business, Global Solta ("Solta") (the "Solta IPO"). See See "Separation of the Bausch + Lomb Eye-Health Business and the Solta Medical Business" b
Read more →BHC▼ -27.1%on this newsshared move
Investor Contact: Media Contact: Christina Cheng Lainie Keller christina.cheng@bauschhealth.com lainie.keller@bauschhealth.com (908) 927-1198 Arthur Shannon arthur.shannon@bauschhealth.com (514) 856-3855 (877) 281-6642 (
Investor Contact: Media Contact: Christina Cheng Lainie Keller christina.cheng@bauschhealth.com lainie.keller@bauschhealth.com (908) 927-1198 Arthur Shannon arthur.shannon@bauschhealth.com (514) 856-3855 (877) 281-6642 (toll free) BAUSCH HEALTH AND B
Read more →BHCREDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. ARRANGEMENT AGREEM
identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. ARRANGEMENT AGREEMENT BAUSCH + LOMB CORPORATION 12279967 CANADA LTD. 12283778 CANADA LTD.
Read more →BHCREDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. MASTER SEPARATION
identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. MASTER SEPARATION AGREEMENT Dated as of March 30, 2022 Page SCHEDULES iv EXHIBITS
Read more →BHCInvestor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES F
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS AND PROVIDES 2022
Read more →BHCInvestor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free)
Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR SECURED NOTES LAVAL, Quebec,
Read more →BHCInvestor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES IT IS SEEKING
Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) ANNOUNCES IT IS SEEKING TO REFINANCE ITS EXISTING CREDIT AGREEMENT AND CONDITIONAL REDEMPTION OF
Read more →BHCInvestor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH + LOMB CORPORATION FILES REGISTRA
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH + LOMB CORPORATION FILES REGISTRATION STATEMENT AND PRELIMINARY PROSPECTUS FOR PROPOSED INI
Read more →BHC▼ -9.3%on this news
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES T
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES THIRD-QUARTER 2021 RESULTS Third-Quarter 2021 Financial Re
Read more →BHCInvestor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES TOM VADAKETH WIL
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES TOM VADAKETH WILL JOIN BAUSCH PHARMA* AS CHIEF FINANCIAL OFFICER LAVAL,
Read more →BHC▼ -10.8%on this news
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES S
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES SECOND-QUARTER 2021 RESULTS Second-Quarter 2021 Financial
Read more →BHCInvestor Contact: Arthur Shannon arthur.shannon@bauschhealth.com (514) 856-3855 (877) 281-6642 (toll free) Media Contact: Lainie Keller lainie.keller@bauschhealth.com (908) 927-1198
BAUSCH HEALTH ANNOUNCES D. ROBERT HALE HAS RESIGNED FROM ITS BOARD OF DIRECTORS Quebec, June 21, 2021 Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health or the Company ) today announced that D. Robert Hale has resigned from his role as an independent director of the
Read more →BHCRevenues Our revenues were $8,601 million and $8,380 million for 2019 and 2018, respectively, an increase of $221 million, or 3%. The increase was primarily driven by (i) higher net realized pricing of $199 million prima
On August 6, 2020, we announced that we intend to separate our eye-health business into an independent publicly traded entity ("Bausch + Lomb") from the remainder of Bausch Health Companies Inc. (the Separation ). See "Separation of the Bausch + Lomb Eye-Health Business" below fo
Read more →BHCInvestor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ISSUES FORM 8-K FOR 2021
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ISSUES FORM 8-K FOR 2021 ANNUAL MEETING OF SHAREHOLDERS PRESENTATION LAVAL, Quebec,
Read more →BHCInvestor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free)
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH AGREES TO SELL AMOUN PHARMACEUTICALS LAVAL, Quebec, March 31, 2021 - Bausch Health
Read more →BHCInvestor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES CFO SUCCESSION
Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) HEALTH ANNOUNCES CFO SUCCESSION PLAN Eldessouky Will Succeed Paul S. Herendeen as Chief Financi
Read more →BHCInvestor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES AGREEMENT WITH C
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES AGREEMENT WITH CARL C. ICAHN Two New Directors to Be Appointed to Board
Read more →BHCInvestor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH PROVIDES PRELIMINARY UPDAT
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH PROVIDES PRELIMINARY UPDATE ON FOURTH-QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS A
Read more →BHCInvestor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. PROVIDES PR
Investor Contact Media Contact Arthur Shannon Lainie Keller arthur.shannon bauschhealth.com lainie.keller bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. PROVIDES PRELIMINARY UPDATE ON THIRD-QUARTER 2020 FINANCIAL RESULTS A
Read more →BHCInvestor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES
Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES FIRST-QUARTER 2020 RESULTS LAVAL, Quebec, May 7, 2020 -
Read more →BHCAnnual Meeting of Shareholders
Forward-Looking Statements This presentation contains forward-looking information and statements, within not limited to, risks and uncertainties caused by or relating to the evolving the meaning of applicable securities laws (collectively, "forward-looking COVID-19 pandemic, and
Read more →BHCInvestor Contact : Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES IT IS SEEKING
Investor Contact : Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES IT IS SEEKING A REFINANCING AMENDMENT TO ITS EXISTING CR
Read more →BHCth Annual J.P. Morgan Healthcare Conference
38 th Annual J.P. Morgan Healthcare Conference Jan. 13, 2020 Bausch Health: 20/20 VISION A Global, Diversified Health Care Company with Independently Strong Businesses Positioned for the Next Decade 2 This presentation contains forward - looking information and statements, withi
Read more →BHCInvestor/Media Contact: Arthur Shannon arthur.shannon@bauschhealth.com (514) 856-3855 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES SECOND-QUARTER 2019 RESULTS AND RAISES FULL-YEAR GUIDANCE Second-Qua
Investor/Media Contact: Arthur Shannon arthur.shannon@bauschhealth.com (514) 856-3855 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES SECOND-QUARTER 2019 RESULTS AND RAISES FULL-YEAR GUIDANCE LAVAL, Quebec, August 6, 2019 - Bausch Health Companies Inc. (N
Read more →BHCInvestor/Media Contact: Arthur Shannon arthur.shannon@bauschhealth.com (514) 856-3855 (877) 281-6642 (toll free)
Investor/Media Contact: arthur.shannon@bauschhealth.com (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES EARLY TENDER RESULTS AND EARLY SETTLEMENT DATE FOR CASH TENDER OFFERS FOR SENIOR NOTES LAVAL, Quebec, May 23, 2019 Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch
Read more →BHCInvestor/Media Contact: Arthur Shannon arthur.shannon@bauschhealth.com (514) 856-3855 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES FIRST-QUARTER 2019 RESULTS AND RAISES FULL YEAR GUIDANCE First-Quart
Investor/Media Contact: Arthur Shannon arthur.shannon@bauschhealth.com (514) 856-3855 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES FIRST-QUARTER 2019 RESULTS AND RAISES FULL YEAR GUIDANCE LAVAL, Quebec, May 6, 2019 - Bausch Health Companies Inc. (NYSE/
Read more →BHCThis presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements regarding Ba
2019 Annual Meeting of Shareholders April 30, 2019 Laval, Quebec Exhibit 99.1 This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, st
Read more →BHCInvestor/Media Contact: Arthur Shannon arthur.shannon@bauschhealth.com (514) 856-3855 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES CLOSING OF SENIOR SECURED NOTES AND ADD-ON UNSECURED NOTES
Investor/Media Contact: Arthur Shannon arthur.shannon@bauschhealth.com (514) 856-3855 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES CLOSING OF SENIOR SECURED NOTES AND ADD-ON UNSECURED NOTES, AS WELL AS REDEMPTION OF EXISTING SENIOR NOTES LAVAL, QUEBEC, Mar. 8,
Read more →BHCInvestor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIV
Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR SECURED NOTES AND ADD-ON UNSECURE
Read more →BHCInvestor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES
Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS AND PROVIDES 2
Read more →BHCBausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc. Strategic Acquisition Will Enhance the Salix Gastroenterology Portfolio
\Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc. Strategic Acquisition Will Enhance the Salix Gastroenterology Portfolio LAVAL, Quebec, Dec. 12, 2018 /PRNewswire/ -- Bausch Health Companies
Read more →BHCInvestor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES CLOSING OF INC
Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES CLOSING OF INCREMENTAL AMENDMENT TO ITS EXISTING CREDIT AGREEMENT A
Read more →BHCInvestor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free)
Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) BAUSCH HEALTH TO SEEK INCREMENTAL AMENDMENT TO ITS EXISTING CREDIT AGREEMENT LAVAL, Quebec
Read more →BHCInvestor Contact: Media Contacts: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) Karen Paff karen.paff@salix.com (908)
Investor Contact: Media Contacts: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) Karen Paff karen.paff@salix.com (908) 927-1190 SALIX AND ALFASIGMA WILL INITIATE LATE-STAGE
Read more →BHChas been revised from the "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" included in Part II to the Company's Annual Report on Form 10-K for the year ended
During 2017, the Company divested certain businesses. In 2018, the Company began reallocating assets and resources to other businesses. As a result, during the second quarter of 2018, the Company's CEO, who is the Company's Chief Operating Decision Maker, commenced managing the b
Read more →BHCInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@valeant.com lainie.keller@val
International Headquarters Laval, Quebec H7L 4A8 Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@valeant.com lainie.keller@valeant.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) VALEANT ANNOUNCES CLOSING OF A
Read more →BHCInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Investor Contact: Arthur Shannon arthur.shannon@valeant.com (514) 856-3855 (877) 281-6642 (toll free) Medi
International Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 VALEANT ANNOUNCES LAUNCH OF PRIVATE OFFERING OF NOTES AND UPSIZE OF TERM LOANS LAVAL, QUEBEC, May 17, 2018 - Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") t
Read more →BHCInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Qu bec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@valeant.com lainie.keller@val
International Headquarters 2150 St. Elz ar Blvd. West Laval, Qu bec H7L 4A8 Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@valeant.com lainie.keller@valeant.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) VALEANT ANNOUNCES FIRST-QUA
Read more →BHCExcerpts from the Preliminary Offering Memorandum dated
Excerpts from the Preliminary Offering Memorandum dated October 2, 2017: Summary Historical Consolidated Financial and Other Information The Skincare Sale was completed on March 3, 2017, and the CeraVe , AcneFree and AMBI skincare brands involved in the Skincare Sale contribut
Read more →BHCInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Qu bec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Investor Contacts: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@valeant.com lainie.keller@va
International Headquarters 2150 St. Elz ar Blvd. West Laval, Qu bec H7L 4A8 Investor Contacts: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@valeant.com lainie.keller@valeant.com 514-856-3855 908-927-0617 877-281-6642 (toll free) VALEANT ANNOUNCES SECOND-QUARTER
Read more →BHCInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Investor Contact: Elif McDonald elif.mcdonald@valeant.com 514-856-3855 877-281-6642 (toll free) Media Cont
International Headquarters 2150 St. Elz ar Blvd. Laval, Quebec H7L 4A8 elif.mcdonald@valeant.com 877-281-6642 (toll free) lainie.keller@valeant.com JOINS VALEANT BOARD OF DIRECTORS LAVAL, Quebec, June 19, 2017 - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and T
Read more →BHCInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Investors: Elif McDonald elif.mcdonald@valeant.com 514-856-3855 877-281-6642 (toll fr
International Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Contact Information: elif.mcdonald@valeant.com 877-281-6642 (toll free) lainie.keller@valeant.com VALEANT ANNOUNCES FIRST QUARTER 2017 RESULTS AND RAISES FULL-YEAR ADJUSTED EBITDA GUIDANCE RANGE
Read more →BHCValeant Announces the Early Results of Tender Offers for Its 6.75% SENIOR NOTES DUE 2018
Announces the Early Results of Tender Offers for Its 6.75% SENIOR NOTES DUE 2018 LAVAL, QUEBEC, March 20, 2017 - Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that as of 5:00 p.m. New York City time on March 20,
Read more →BHCInformation: Elif McDonald elif.mcdonald@valeant.com 514-856-3855 877-281-6642 (toll free) Media: Ren e Soto or Chris Kittredge/Jared Levy Sard Verbinnen & Co. 212-687-8080
elif.mcdonald@valeant.com Kittredge/Jared Levy ANNOUNCES PRICING AND UPSIZE OF PRIVATE OFFERING OF SENIOR SECURED NOTES QUEBEC, March 10, 2017 - Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has priced
Read more →BHCInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Elif McDonald elif.mcdonald@valeant.com 514-856-3855 877-281-6642 (toll free) Media:
International Headquarters 2150 St. Elz ar Blvd. Laval, Quebec H7L 4A8 Contact Information: elif.mcdonald@valeant.com 877-281-6642 (toll free) Chris Kittredge/Jared Levy Sard Verbinnen & Co. VALEANT ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR SECURED NOTES LAVAL, QUE
Read more →BHCInformation: Elif McDonald elif.mcdonald@valeant.com 514-856-3855 877-281-6642 (toll free) Media: Ren e Soto or Chris Kittredge/Jared Levy Sard Verbinnen & Co. 212-687-8080 VALEANT COMPLETES APPROXIMATELY $1.1 BI
Contact Information: elif.mcdonald@valeant.com 877-281-6642 (toll free) Chris Kittredge/Jared Levy Sard Verbinnen & Co. COMPLETES APPROXIMATELY $1.1 BILLION PAY DOWN OF SENIOR SECURED TERM LOANS FROM DIVESTITURES; TO SEEK REFINANCING AND AMENDMENT OF CREDIT AGREEMENT Quebe
Read more →BHCInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Elif McDonald 514-856-3855 877-281-6642 (toll free) elif.mcdonald@valeant.com Media:
St. Elz ar Blvd. West elif.mcdonald@valeant.com Kittredge/Jared Levy TO SELL DENDREON TO SANPOWER GROUP FOR Quebec, January 9, 2017 - Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that its affiliate has entered into
Read more →BHCInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Investors: Laurie W. Little laurie.little@valeant.com or Elif McDonald elif.mcdonald@
International Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 laurie.little@valeant.com elif.mcdonald@valeant.com 877-281-6642 (toll free) Chris Kittredge/Jared Levy Sard Verbinnen & Co. VALEANT PHARMACEUTICALS REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS
Read more →BHCInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little laurie.little@vale ant.com or Elif McDonald elif.mcdonald@valeant.co
International Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Contact Information: laurie.little@valeant.com elif.mcdonald@valeant.com 877-281-6642 (toll free) Chris Kittredge/Jared Levy Sard Verbinnen & Co. VALEANT PHARMACEUTICALS ANNOUNCES THE ADDITION OF
Read more →BHCInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little 949-461-6002 laurie.little@valeant.com Elif McDonald 905-695-7607 el
International Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Contact Information: laurie.little@valeant.com elif.mcdonald@valeant.com Chris Kittredge/Jared Levy Sard Verbinnen & Co. VALEANT PHARMACEUTICALS RECEIVES NOTICE OF DEFAULT Notice Does Not Acceler
Read more →BHCOF VALEANT PHARMACEUTICALS INTERNATIONAL, INC., DATED APRIL 22, 2016 ex99-1.htm International Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Info
International Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: laurie.little@valeant.com elif.mcdonald@valeant.com Ren e Soto/Jared Levy Meghan Gavigan Sard Verbinnen & Co. Sard Verbinnen & Co. 212-687-
Read more →Competitive Position
How BHC ranks across every disease it competes inCompetitive Position is a premium feature
See how BHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial